FOXM1-Induced Resistance to Oxaliplatin in Gastric Cancer Cells Partly Mediated by Mcl-1

Strategic Insights -

Research conducted at the University of Pittsburgh has shed light on the regulatory mechanism of the anti-apoptotic protein Mcl-1 in gastric cancer cells, revealing a novel target for enhancing sensitivity to oxaliplatin. The study found that Forkhead box M1 (FOXM1) expression levels were positively correlated with Mcl-1 expression, both of which were associated with poor prognosis in patients treated with oxaliplatin. Furthermore, reporter assays showed that FOXM1 upregulated the promoter activity of the Mcl-1 gene, and electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays demonstrated that FOXM1 could bind to a specific site in the promoter region of the Mcl-1 gene.

Key Takeaways:

  • Mcl-1 is an anti-apoptotic protein that plays a crucial role in sensitivity to chemotherapy drugs in gastric cancer.
  • FOXM1 is a transcription factor that upregulates the expression of Mcl-1, contributing to resistance to oxaliplatin in gastric cancer cells.
  • The suppression of the FOXM1/Mcl-1 pathway induced apoptosis and increased sensitivity to oxaliplatin, while its enhancement inhibited apoptosis and decreased sensitivity to oxaliplatin in gastric cancer cells.
  • Targeting the FOXM1/Mcl-1 pathway may be a novel strategy to enhance sensitivity to oxaliplatin in gastric cancer.
  • The study suggests that the regulatory mechanism of Mcl-1 in gastric cancer cells is complex and involves the interaction of multiple factors, including FOXM1 and other transcription factors.
  • The research has significant implications for the development of new cancer therapies, particularly in the treatment of gastric cancer.

Statistics:

  • Gastric cancer accounts for a significant proportion of cancer-related deaths worldwide, with more than 1.2 million new cases diagnosed annually (Source: International Agency for Research on Cancer).
  • Oxaliplatin is a widely used chemotherapy drug, but resistance to the drug is a major obstacle in its treatment of gastric cancer (Source: National Cancer Institute).
  • The study found that 70% of gastric cancer specimens showed positive correlation between FOXM1 and Mcl-1 expression levels (Source: Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms, 2015).
  • The suppression of the FOXM1/Mcl-1 pathway led to a significant increase in apoptosis in gastric cancer cells, from 20% to 60% (Source: Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms, 2015).

Sources:

  • Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms, 2015; 1849(3): 290-299.
  • C.J. Hu, et al. (2015). The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells. Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms, 1849(3): 290-299.